Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Opgen Inc (OPGN)

Opgen Inc (OPGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Navigating the Roller Coaster of Recent Penny Stock Surges

Recent surges in penny stocks, like Secoo (SECO), Tempest Therapeutics (TPST), and OpGen (OPGN), have fueled speculation and excitement in penny stocks.

SECO : 0.4049 (+5.17%)
OPGN : 1.5000 (-17.13%)
TPST : 0.9055 (+1.33%)
OpGen (NASDAQ: OPGN) Reports Positive Data from Clinical Trial for Unyvero as Diagnostic for UTI

OpGen, Inc. (NASDAQ: OPGN) is engaged as a precision medicine company that is focused on developing molecular diagnostics and bioinformatics

OPGN : 1.5000 (-17.13%)
OpGen to Provide Business Update and Financial Results for the Second Quarter 2022 on August 11th at 4:30 p.m. Eastern Time

ROCKVILLE, Md., July 28, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a...

OPGN : 1.5000 (-17.13%)
OpGen Subsidiary Ares Genetics GmbH Enters into Collaboration Agreement with the Belgian National Reference Centre for Invasive S. pneumoniae at UZ Leuven

Collaborators aim to develop and evaluate computation tools, including predictive models for whole genome sequencing-based antibiotic susceptibility...

OPGN : 1.5000 (-17.13%)
OpGen Announces Preliminary Unaudited Revenue and Cash Position for Second Quarter 2022 and Provides Business Update

Preliminary Total Revenue for Q2 2022 was approximately $1.0 millionCash as of June 30, 2022 was approximately $16.6 millionFirst commercial customer...

OPGN : 1.5000 (-17.13%)
OpGen Announces Publication of Results of Unyvero Hospitalized Pneumonia (HPN) Panel for Detection of Bacterial Respiratory Tract Pathogens from Serial Specimens Collected from Hospitalized COVID-19 Patients

Results were published in the European Journal of Clinical Microbiology & Infectious Diseases Serial specimen analysis confirms correct detection of...

OPGN : 1.5000 (-17.13%)
OpGen Announces 1,000th Patient Sample Enrolled in Clinical Trial for Unyvero Urinary Tract Infection Panel

Prospective multicenter trial for the Unyvero UTI panel recruited its 1,000th prospective patient sampleFourth trial site added to optimize enrollment for...

OPGN : 1.5000 (-17.13%)
OpGen Subsidiary Curetis and Leader Life Sciences Enter into Unyvero Distribution Partnership for U.A.E. and Qatar

Exclusive distribution agreement for initial term of three yearsLeader Life Sciences commits to minimum purchase of 8 Unyvero systems during initial term...

OPGN : 1.5000 (-17.13%)
OpGen Announces Publication of Results from Major Clinical Study Using Unyvero Hospitalized Pneumonia (HPN) Panel in the Lancet Respiratory Medicine

208 patients enrolled in a prospective, randomized, controlled, multicenter, interventional trial Unyvero reduced the use of inappropriate antibiotic...

OPGN : 1.5000 (-17.13%)
OpGen Reports First Quarter 2022 Financial Results and Provides Business Update

Total Q1 2022 revenues of $0.5 millionCash position of approximately $30.7 million to reach into Q1-2023 Management conference call scheduled for May 12,...

OPGN : 1.5000 (-17.13%)

Barchart Exclusives

1 Cathie Wood Stock to Buy Now and Hold for Long-Term Upside
This Cathie Wood stock just received an upgrade from an analyst who recommends it for long-term investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar